single10MG
TB-500
10MG Protocol
TB-500 10MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks based on research protocol
Reconstitution
3.0 mL BAC water
Supports wound healing and tissue repair via cell migration and angiogenesis
May support collagen deposition and tissue regeneration in preclinical models
Potential indirect anti-inflammatory/anti-fibrotic effects observed in animal research
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 500 mcg | 15 |
| 2 | Weeks 3–4 | 600 mcg | 18 |
| 3 | Weeks 5–8 | 750 mcg | 23 |
| 4 | Weeks 9–12 | 1000 mcg | 30 |
Inject once daily
8–12 weeks; optional extension to 16 weeks based on research protocol
TB-500 is described as a synthetic fragment corresponding to the active N-terminal region of thymosin beta-4, specifically the heptapeptide sequence Ac-LKKTETQ. In the protocol’s ‘How This Works’ section, this region is associated with actin-binding and cell-migration biology—processes that are central to tissue remodeling. TB-500 is presented as supporting angiogenesis and wound repair by promoting cell motility and blood-vessel formation, with animal-model findings that include enhanced collagen deposition and faster healing timelines at injury sites. The page also notes emerging research suggesting TB-500 may behave as a prodrug, being cleaved into a smaller active pentapeptide metabolite that contributes to biological activity. Overall, the mechanism is framed as facilitating coordinated repair signals (migration, angiogenesis, extracellular-matrix remodeling) rather than a single-target hormonal pathway, with the important caveat that large-scale human clinical data are limited.
Mild injection-site reactions (redness/tenderness)
Limited human safety data
no large-scale clinical trials specific to TB-500 described
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)